Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Blueprint Medicines exceeds revenue expectations, eyes growth opportunities in 2023

Blueprint Medicines delivered strong financial results and outlined growth strategies for 2023, driven by AYVAKIT's performance.
The company faces uncertainties around label negotiation but benefits from strong market access and proactive market expansion efforts.
Opportunities lie in upcoming data presentations, CDK2 program updates, and capturing additional market share in the ISM segment.

Blueprint Medicines reports strong Q1 performance and growth opportunities

Blueprint Medicines showcased strong financial performance, a robust growth strategy, and promising pipeline advancements during the Q1 earnings call. While facing challenges in managing expenses and differentiating sales, the company is well-positioned to capitalize on opportunities in driving AYVAKYT sales and educating providers on SM treatment urgency.

Blueprint Medicines reports strong Q2 results and eyes market expansion

Blueprint Medicines demonstrated solid financial performance and positive market reception for AYVAKIT and BLU-222.
While facing challenges in operational execution and market competition, the company has opportunities for growth through portfolio expansion and market diversification.
Overall, Blueprint Medicines is well-positioned to capitalize on the success of AYVAKIT and the potential of BLU-222 in driving future growth and innovation.

Blueprint Medicines excels in Q3, eyes sustainable growth in 2024

Blueprint Medicines delivered strong Q3 results with a focus on sustainable revenue growth and pipeline advancement.
The company's strengths lie in AYVAKIT's market adoption, high patient retention rates, and promising pipeline assets.
Challenges include managing operating expenses, decreasing cash burn, and expanding market penetration for AYVAKIT.
Opportunities exist in developing new assets, presenting upcoming data, and achieving significant growth in 2024.

Blueprint Medicines reports robust 2023 performance and targets $2B peak sales

Blueprint Medicines' strong 2023 performance with AYVAKIT driving revenue growth sets the stage for continued success in 2024, aiming for peak sales exceeding $2 billion.
Strategic focus on expanding market presence, advancing pipeline assets, and maintaining financial discipline positions the company for sustained growth and profitability.
Opportunities lie in maximizing AYVAKIT's market potential, leveraging BLU-808 in inflammatory disorders, and exploring strategic growth avenues in cancer treatment.

Blueprint Medicines reports robust Q1 earnings, eyes strategic partnerships

Blueprint Medicines' strong financial performance, focus on sustainable growth, and strategic expansion into new therapeutic areas position the company for long-term success. Addressing challenges in physician adoption and patient prescription rates while leveraging growth opportunities in strategic partnerships and compound expansion will be crucial for future growth.

Blueprint Medicines excels in Q3 with robust AYVAKIT sales

Blueprint Medicines delivered strong revenue growth driven by AYVAKIT sales, showcasing high compliance and demand. With a focus on long-term growth and financial stability, the company aims to expand its impact with BLU-808 and maintain strong capital allocation priorities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs

JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim Tommie Reerink - Goldman Sachs Derek Archila - Wells Fargo Mike Ulz - Morgan Stanley Ami Fadia - Needham Markus Schweiger - Oppenheimer Peter Lawson - Barclays Laura Prendergast - Raymond James David Lebowitz - Citi Sudan Loganathan - Stephens Operator Good morning. My name is Nadia, and I'll be your conference operator today.

Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago.

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- --  On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance.

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

CRISPR Therapeutics

Exelixis

Amicus Therapeutics

Verona Pharma

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?

CAMBRIDGE, Mass. , Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join

LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation Is Being Investigated For Securities Fraud And Stakeholders With Losses Should Contact The Schall Law Firm

CAMBRIDGE, Mass. , Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m.

Blueprint Medicines to Present at Upcoming Investor Conferences

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Engaged In Securities Fraud And Shareholder Participation In An Investigation Is Encouraged By The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Possible Securities Law Violations And Investors Are Urged To Join The Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Defrauded Shareholders And The Schall Law Firm Wants Those With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Potential Securities Law Violations And Investors Are Encouraged To Join

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Defrauded The Public And The Schall Law Firm Seeks Shareholder Participation In An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Blueprint Medicines Corporation Committed Securities Related Improprieties And Investors Should Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation's Possible Securities Fraud And Investors Are Invited To Assist

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Violated Securities Regulations And The Schall Law Firm Seeks Shareholders' Help In The Inquiry

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Blueprint Medicines Stock (BPMC)